BUENOS AIRES (Reuters) - Argentines living with HIV/AIDS and medics say spending cuts under libertarian President Javier ...

Conducted by Emory University and Grady Health System and funded by Gilead, the trial showed that Lenacapavir offers a ...

Argentina's HIV/AIDS treatment programs are facing cuts under President Milei's austerity measures, reducing budgets by 67% ...

Argentinian President Javier Milei has raised concerns for the HIV/AIDS patients and medics with his fiscal deficit ...

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...

Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...

A twice-yearly shot shows 100% effectiveness against HIV, but concerns arise over accessibility in Latin America and other ...

Another drugmaker, Viiv Healthcare, also left out most of Latin America when it allowed generics of its HIV prevention shot ...

Lenacapavir, an injectable PrEP taken twice a year, demonstrated 96% efficacy in preventing HIV infections in a global Phase ...

Discover the groundbreaking results of Lenacapavir, a twice-yearly injection that reduces HIV infection risk offering an ...